Posted by Michael Wonder on 24 Jun 2021
China's first CAR-T cell therapy approved Fosun Kite axicabtagene ciloleucel (FKC876)
24 June 2021 - The first CAR-T cell therapy approved by NMPA: opening a new era of cell therapy in China.
On 23 June 2021, Fosun Kite Biotechnology announced its autologous CD19 directed CAR-T cell therapy axicabtagene ciloleucel (FKC876) has been approved by China National Medical Products Administration for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
